BioLife Solutions Inc

NASDAQ:BLFS

Earnings Call Transcript 2023-Q1

[Operator]

Hello. My name is Mallory, and I will be your conference operator today. At this time, I would like to welcome everyone to the Q1 2023 BioLife Solutions, Inc. Earnings Conference Call. [Operator Instructions]. Thank you.

I would now like to turn the conference over to Troy Wichterman, Chief Financial Officer. Please go ahead.

[Troy Wichterman, CFO]

Thank you, Mallory. Good afternoon, everyone, and thank you for joining us. With me on today's call is Mike Rice, Chairman and Chief Executive Officer.

Earlier today, we issued a press release announcing our financial results and operational highlights for the first quarter of 2023, which is available at biolifesolutions.com. As a reminder, during this call, we will make certain projections and other forward-looking statements regarding future events or the future financial performance of the company. These statements are subject to risks and uncertainties that may cause actual results to differ materially from expectations.

For a detailed discussion of the risks and uncertainties that affect the company's business and that qualify as forward-looking statements, I refer you to our periodic reports and other public filings filed with the SEC. Company projections and forward-looking statements are based on factors that are subject to change, and therefore, these statements speak only as of the date they are made. The company assumes no obligation to update any projections or forward-looking statements, except as required by law.

During this call, we will speak to non-GAAP or adjusted results. Reconciliations of GAAP to non-GAAP or adjusted financial metrics are included in the press release we issued this afternoon. These non-GAAP or adjusted financial metrics should not be viewed as an alternative to GAAP. However, in light of our historic M&A activity, we believe that the use of non-GAAP or adjusted metrics provides investors with a clearer view of our current financial results when compared to prior periods.

Now I'd like to turn the call over to Mike Rice, Chairman and CEO of BioLife Solutions.

[Michael Rice, Chairman & CEO]

Thank you, Troy. I'd like to begin our call by discussing our announcement today that we are actively exploring strategic alternatives for our Stirling ULT and Custom Biogenic Systems Cryogenic Freezer businesses, which could include out-licensing our proprietary IP, changing our go-to-market approach, and outright divesting these assets.

As you know, we had high expectations for the benefits of scale the acquisitions could bring to BioLife and for the potential to cross-sell our core high-margin biopreservation media solutions with CBS and Stirling Differentiated Freezers. We built BioLife organically and inorganically with acquisitions like Stirling and CBS and while we certainly realized many benefits of scale, after much analysis and consultation with external advisers, we've now come to a decision to explore our options for these businesses.

The capital intensity and a lower margin volatile sales cycle business has not been beneficial to our core growth rate and corporate profitability and has not placed us in the peer group where we belong. With the global supply chain negative impact still ongoing and the volatile market dynamics in play, the expected merits of these 2 acquisitions have failed to materialize to the extent we expected. I take my job responsibility to create shareholder value very seriously and with support of the Board and our leadership teams to let the decision to explore a course change.

To support these explorations, we've engaged a strategic advisory firm to manage outreach to and inbound inquiries from parties interested in licensing our IP and/or acquiring these businesses. To be clear, our strategic decision is to explore options, one of which is to potentially put our innovative CBS and Stirling businesses in the hands of other parties that can better leverage their operations, supply chain and cost structure to maximize their business model. If divesting is ultimately the best option, and we complete both, we will have returned BioLife to a higher multiple peer group with a portfolio of leading high-margin, high-growth recurring revenue products and services that are class-defining.

We believe any potential divestitures will preserve and enhance the synergies among our biopreservation media products, Sexton Cell Processing tools, evo Cold Chain management service and SciSafe biologic storage services. This potential portfolio optimization will help us to return to an enhanced gross and EBITDA margin company with industry-leading growth. It will also importantly and significantly reduce working capital cash burn, providing more flexibility to invest in and build upon our potent complementary offering where everything fits.

It's clear when we look at these assets on a go-forward basis, that our exploration of strategic alternatives is the right decision at the right time for the right reasons for the company and for shareholders. We recognize that it's frustrating when strategy and tactics fail to produce anticipated results. But as business people, we work for you, the shareholders, and we must be thoughtful and decisive. In our view, looking at the key financial metrics, we've built an incredibly powerful company.

Going forward, acquiring additional high-margin recurring revenue businesses still make strategic and economic sense and our learnings from these 2 deals will be applied in the future so that we focus only on high-margin, high-growth businesses that can deliver additive recurring revenue.

To conclude, I'd like to acknowledge the sustained improvement efforts of our leadership team, middle management, and line workers at CBS and Stirling who have put these assets in the best shape ever from the perspectives of quality, operations, supply chain, financial accounting, CRM, HR systems and sales and marketing. The R&D activities have been focused and well managed through a rigorous stage-gate review and approval process. Without this work, we would not be in a strong position to explore strategic alternatives. We appreciate and recognize that operating through a potential divestiture process can lead to uncertainty for our team members and customers, and I'm proud and grateful for their dedication and support. Our team can count on us to retain talent and reward loyalty and results. Our customers can count on us to continue to produce and deliver high-quality products.

Now I'll switch back to discussing our Q1 performance. The team continued to gain new CGT and biopharma customers, driving continued adoption of our Cell Processing and Storage and Storage Services platforms, while our Freezer platform experienced similar disruptions that others have reported in recent quarters.

Turning to Q1 revenue and customer highlights. Total revenue was $37.7 million, representing a 4% increase over Q1 2022. Excluding COVID-related revenue from Q1 last year, total revenue growth was 16% driven by a 28% increase in biopreservation media revenue. In Q1, we sold and shipped products or provided services to 197 new unique customer sites across our 3 products and services platforms. A large portion of our total revenue continues to come from existing customers as we penetrate deeper and pitch our integrated solutions to take more share of their spend for manufacturing, storage and distribution products and services.

In each of the last 5 quarters, we gained over 150 new customer sites, building a phenomenal pipeline of early-stage users that we will carefully nurture and support to drive future growth. New Q1 customer sites by product and service line included 9 more now using biopreservation media, 5 new ThawSTAR users, 17 new evo Cold Chain end users, 15 new Cryogenic Freezer and accessory customer sites, 121 new Stirling ULT Freezer and accessory customer sites, 22 new Biostorage customers, and 8 new Cell Processing customers now using Sexton products.

For our Cell Processing platform in Q1, we received confirmation that our solutions will be used in at least 20 additional clinical trials for new cell and gene therapies. We estimate that our biopreservation media products have been used in or are planned to be used in over 630 customer clinical applications, and our Sexton Cell Processing tools are in about 140. For both biopreservation media and Sexton products, we also remain confident that each customer clinical application, if approved, could generate annual revenue in a range of $500,000 to $2 million. To date, our Cell Processing solutions are used in 14 approved therapies, including the recently approved Omisirge by Gamida Cell. We expect to be able to continue to take share from home-brew preservation cocktails as awareness grows of the critical role our engineered media formulations play in reducing risk for CGT companies.

I'll reiterate the 5 strong catalysts we expect to support our growth estimates since each will increase the number of manufactured doses and hence, the demand for our biopreservation media, Sexton Cell Processing solutions, evo Cold Chain rentals and SciSafe storage services. Number one, new de novo CGT approvals; two, approvals of existing commercial therapies in new geographies; three, approvals of existing commercial therapies and new indications; four, approvals of existing commercial therapies as first- or second-line treatment; and five, the eventual shift to allogeneic therapies.

Turning to our Storage and Storage Services platform, which includes evo Cold Chain rentals and SciSafe Storage Services, we gained 39 new customer sites in Q1, 22 for biologic storage services and 17 for evo. On the SciSafe side of the platform, we also continue to penetrate further in existing customers and have a very strong pipeline of high-value, long-term contract opportunities, and we expect another banner year for SciSafe.

On the evo Cold Chain management side of the platform, we continue to drive the business as evidenced by 135% increase in quarterly shipments, specifically of approved cell therapy products. As we've reported before, evaluations and validation shipments by leading CGT companies are ongoing, and we expect continued adoption. One global pharma company has confirmed that upon a completed successful validation, they intend to switch up to 100% of both of their approved cell therapy shipments from the leading provider over to our evo platform early next year. This is excellent market validation as internally, we modestly modeled a 50-50 split of shipments between evo and the incumbent.

And finally, our Freezers and Thaw Systems platform. We shipped first-time orders to 141 new customer sites, including 121 now using Stirling products. Customers continue to recognize the value proposition of our Freezer offerings based on tight temperature regulation, reduced power consumption, reduced heat generation and less noise pollution as these support their goal of reducing the negative environmental impact of their operations.

Q1 revenue was lumpy and off pace due to the now well-understood tightening biotech capital equipment funding and delayed purchase decisions due to economic uncertainty. On a positive note, we have a strong opportunity pipeline of potential Stirling Freezer orders, forecasted to close this year.

Now I'll turn the call back over to Troy to present our financials for Q1. Troy?

[Troy Wichterman, CFO]

Thank you, Mike. Total revenue for the first quarter of 2023 was $37.7 million, representing a 4% increase over Q1 of 2022 and excluding COVID-related revenue from Q1 2022, growth was 16%, which was driven by a 28% increase in biopreservation media revenue. There was no COVID-related revenue in Q1 2023 compared to 10% of total revenue in Q1 2022.

Cell Processing platform revenue was $19 million, up 27% over the same period in 2022. Storage and Storage Services platform revenue was $5.7 million, down 5% over the same period in 2022. Excluding COVID-related revenue from Q1 2022, revenue in Q1 2023 increased 98%. Freezers and Thaw Systems platform revenue was $13 million, down 15% over the same period in 2022. Excluding COVID-related revenue from Q1 2022, revenue in Q1 2023 decreased 12%.

Adjusted gross margin for the first quarter of 2023 was 37% compared with 33% for the first quarter of 2022 and 32% for the fourth quarter of 2022. The positive impact sequentially when compared to prior year was primarily due to product mix and lower inventory write-off charges, partially offset by lower gross margins at SciSafe due to the decrease in COVID-related revenue without an associated decrease of infrastructure costs.

GAAP operating expenses for Q1 2023 were $51.3 million versus $44.2 million in Q1 2022. Adjusted operating expenses for Q1 2023 totaled $25.5 million compared with $20.1 million in Q1 2022. The increase in operating expenses was primarily driven by increased headcount, consulting fees and infrastructure costs to support our long-term growth objectives.

Our adjusted operating loss for the first quarter of 2023 was $11.4 million compared with $8.3 million in Q1 2022. Adjusted EBITDA for the first quarter of 2023 was negative $1.9 million compared with negative $1.1 million for the first quarter of 2022. In Q1 2023, we had nonrecurring expenses of approximately $3 million, consisting of strategic consulting fees, a planned severance payment for our former COO, indirect taxes and a discrete bad debt write-off. Excluding these nonrecurring expenses, adjusted EBITDA would have been positive $1.1 million. We expect adjusted EBITDA improvement throughout the year, resulting in full year 2023 positive adjusted EBITDA.

Our cash and marketable securities balance at March 31, 2023, was $56.9 million compared with $64.1 million at December 31, 2022. Taking into consideration our adjusted EBITDA of negative $1.9 million, cash used in Q1 2023 was primarily related to unfavorable working capital adjustments of $840,000, largely due to the timing of raw material deliveries related to biopreservation media, capital expenditures of $3.3 million and purchases of assets [indiscernible] $1 million.

Turning to 2023 revenue guidance. Management is reaffirming full year guidance is expected to be in the range of $188 million to $202 million, reflecting year-over-year and organic growth of 16% to 25%. Excluding COVID-related revenue, year-over-year growth of 26% to 35%. Revenue guidance for 2023 does not include any COVID-related revenue.

Total revenue expectations for 2023 include the following platform contributions, Cell Processing platform, $89 million to $93 million, an increase of 30% to 35% over 2022; Storage and Storage Services platform, $26.5 million to $30 million, an increase of 0% to 13% over 2022, excluding COVID-related revenue, year-over-year growth of 64% to 86%; Freezers and Thaw Systems platform, $72.5 million to $79 million, an increase of 9% to 18% over 2022, excluding COVID-related revenue, year-over-year growth of 13% to 23%. Finally, in terms of our share count, as of May 10, we had 43.5 million shares issued and outstanding and 46.3 million shares on a fully diluted basis.

Now I'll turn the call to Mike.

[Michael Rice, Chairman & CEO]

Thanks, Troy. I'd like to summarize 4 key takeaways from Q1 and today's call. First, BioLife Solutions is a critical, highly trusted tools and services provider to the cell and gene therapy industry. We've built a valuable portfolio of solutions that's helped CGT developers increase their likelihood of success by reducing risk in their manufacturing, storage and distribution workflows. Number two, demand for our portfolio of class-defining bioproduction tools and services remain strong. And it's important to remember that we're still in the early phase of CGT approvals and the growth of this exciting industry. We are very well entrenched and intent on securing and maintaining a position as a premier enabling CGT tools and services provider. Number three, our decision to explore strategic alternatives for our 2 Freezer businesses was made carefully after much analysis and consultation with our Board and external advisers.

We're keenly focused on options to reposition our portfolio only on the high-margin, high-growth recurring revenue streams that define us. And number four, order volume to date so far in Q2 is strong across our portfolio. For the rest of 2023, we will focus on running the business efficiently, and managing the exploration of strategic alternatives for our Freezer businesses.

Now I'll turn the call back over to the operator to take your questions. Mallory?

[Operator]

[Operator Instructions]. Your first question comes from Jacob Johnson with Stephens.

[Jacob Johnson, Stephens Inc.]

Mike, maybe starting where you started on the call today, just on the strategic alternatives for the Freezer businesses. You outlined a couple of options, but it seems like a potential sale top of mind. So can you just talk about how you think the potential outcomes from the strategic review? And maybe any kind of thoughts on the time line around that?

[Michael Rice, Chairman & CEO]

Yes. Thanks, Jacob. Well, I want to be really clear that it's not a foregone conclusion that divesting is the only thing we're looking at or the only outcome that could materialize. We have a number of things we're looking at, and it's still pretty early, but we've got a great advisory firm helping us navigate this. And for us, it's just early, and we're all about obviously picking the best option that creates the most shareholder value. Too soon to tell you in terms of a time line when something might happen.

[Jacob Johnson, Stephens Inc.]

Got it. Fair enough. And then maybe the other question just around that in the press release, you reiterated the $250 million of revenue, 50% gross margin, 30% EBITDA targets. Obviously, if you were to divest the Freezer business, that would be a chunk of revenue that would probably make that difficult. But I guess I'm more curious on the other side of things. You highlighted the profitability of the underlying business. Kind of any kind of commentary you could give us on just kind of how much the Freezers are weighing on profitability right now?

[Michael Rice, Chairman & CEO]

Yes. It's a really good question, Jacob. I appreciate you asking. Well, clearly, if we were to invest one or both, we'd have to issue some updated not only guidance, but also some mid- to long-term financial aspirational goals, which we would do once we had a clear vision of how things would shake out. To the last comment that you made to the extent the Freezers are weighing down the profitability, it is material. I mean I'll just say that with full potency it’s a material way down relative to the other parts of the business.

[Jacob Johnson, Stephens Inc.]

Okay. And then, Mike, maybe last question. Some other companies have reported this earnings season obviously, the macro has been a headwind, you talked about that with regard to Freezers. But as it pertains to China, I think that's an area where maybe you saw some traction from -- on the distributor side of things. Have you seen anything from your distributors that would suggest any weakness out of China as it maybe relates to the media business?

[Michael Rice, Chairman & CEO]

Not at all yet. In fact, if I just think about the last, I don't know, a couple of clinical support engagements that Dr. Mathew, our CSO is involved in, they are from China. And so I don't have any read-throughs from Marcus or the sales team that the indirect sales in that part of the world and APAC are soft sequentially or year-over-year. So no to the contrary.

[Operator]

The next question comes from Thomas Flaten with Lake Street Capital Markets.

[Thomas Flaten, Lake Street Capital Markets]

I'm thinking with the concept -- sticking with the concept of the macro, given the softness in Freezer sales in the first quarter, just wanted to get -- or maybe you can help us contextualize some of those macro headwinds, given that you're keeping the guide as it is for that segment of the business?

[Michael Rice, Chairman & CEO]

Right, Thomas, and that's a great place to go to. We certainly were looking at a lot of factors relative to the guide for this year. And I'm happy to tell you that, just to expand a little bit of a comment I made on my prepared remarks that when we look at the pipeline of mostly ULT Freezers that are classified as high confidence to close this year, it's a significant number. I mean it's a big, big number. It's much bigger than I thought, and that's not all the opportunities. Those are just the ones that have made it to the stage where it's considered high confidence to close. So -- and we're not even halfway done through the year. So on the basis of that, with one soft quarter, it would not have been prudent for us to cut the guide in the Freezers and hence, the overall guide. So as we stand here right now on this call on May 10, I'm confident we're going to hit that number, and we're going to come into the range of the total revenue. But yes, if not for the latter, if that not have materialized, we'd probably be having a different conversation.

[Thomas Flaten, Lake Street Capital Markets]

Got it. And I don't know how much you can say about the large pharma customer that you guys highlighted in the press release. But I'm curious, maybe you could walk us through kind of some of the, I guess, the wins you had, I'm sure there was more than one factor that allowed them to flip from the incumbent to you guys. But any color you can give us on that sales process and kind of what -- what feedback they provided to you?

[Michael Rice, Chairman & CEO]

Yes. In a word, I'd say thorough or another word, I'd say vigorous. Not to -- not to the pipe cleaner [ph] process we went through a couple of years ago with the other leading CGT company with a couple of true therapies. But yes, this one is pretty intense, and we're at the right place in the organization in terms of the decision makers on their side. And we've got, as you can imagine, an army of folks on our side who are meeting with this customer, not weekly, but almost. And there's a project plan that's being marched against in a series of go/no-go sort of e-valve validation steps. But when pressed specifically, and I asked our team, hey, if this does go well in our way, what would we expect in terms of the split of shipments and the direct feedback from the customer was up to 100%, which is much higher than we anticipated because as I mentioned a few minutes ago, we just -- we modeled 50-50 as sort of a modest assumption. But if this goes, that's going to be very meaningful for us and now obviously very meaningful for the incumbent in terms of the impact on them.

[Thomas Flaten, Lake Street Capital Markets]

Got it. And then one quick final one for me. Now that you're -- and I think you said 14 approved cell and gene therapies now that you guys are involved with. Has that allowed you to validate the revenue range of the $500,000 to $2 million that we've talked about for a few years? Any suggestion that, that might not be the right range of revenues for commercial products?

[Michael Rice, Chairman & CEO]

Well, I appreciate you asking. I still think it's probably a little low on the high end, but it's still early because, again, the ones we're in there really with a couple of exceptions, they're pretty recently approved. So we just need a few quarters of their track record to see what's going to happen.

[Operator]

The next question comes from Chad Wiatrowski with TD Cowen.

[Chad Wiatrowski, TD Cowen]

Just one on OpEx. How do we think about OpEx sort of the cadence throughout the rest of the year? And maybe how the strategic alternatives of the Freezer business could impact that?

[Troy Wichterman, CFO]

Yes. So as far as OpEx for the rest of the year, I did mention some nonrecurring charges in Q1. If you were to back those out and then grow it, not quite in line with the revenue growth, but again, growing to support our revenue growth, that's a good way to look at the OpEx...

[Chad Wiatrowski, TD Cowen]

Just on the macro headwinds, again, obviously seeing sort of the CapEx issues from biotech and pharma. But on the R&D side, are you seeing like any delays in clinical trial time lines or potential headwinds on that front?

[Michael Rice, Chairman & CEO]

Fair question, Chad. And I can't speak specifically to it, but I would certainly support that we are seeing some of that. But the thing to remember is in the early stages, these aren't meaningful revenue contributors. So it's not really an impact. They don't buy that much in the early days because the trial enrollment is pretty small, right?

[Operator]

Your next question comes from Paul Knight with KeyBanc.

[Paul Knight, KeyBanc Capital Markets]

Now I know with the Stirling and CBS, one of the intentions was to create some cross-selling synergy. What are your thoughts now? Have you -- are you changing -- will you change the way the Cell Processing platform products and the services products are sold? So what are you planning to do on any channel marketing modifications? That's my first question.

[Michael Rice, Chairman & CEO]

Good place to start, Paul. Yes. Well, I think what we've learned, one of the key learning takeaways is that despite our deep contacts and the C-suite in that, there are different decision makers, folks who buy capital equipment, particularly downstream to the folks that were closer to, which are in the processing upstream side of the house. And our assumption was that we could leverage those relationships. But my sense is now just to be practical about it, Freezers are seen maybe inappropriately, but they're largely seen as commodities. And then those are sort of relegated to the domain of the procurement people as opposed to technical buyers or scientific buyers. And that just kind of is what it is.

So with respect to what will we do to change it, well, we really have to think about the current distributors, how productive they are, where are their strengths, where do they lie? Are there alternative distributors? If we think about a potential to divest the businesses, what's the channel those companies have and how strong are they and whatnot? And then there's also this idea to out-license the technology to someone who just embeds our IP in their own freezers. So there's a lot of stuff swirling, and I'm just thankful we've got some really smart folks here and on the outside helping us navigate the options.

[Paul Knight, KeyBanc Capital Markets]

And then the other part, I'm sure, is going on is Sexton and the services side seem to have exceeded your expectations here over the last couple of years. Can you talk to Sexton and the potential there, specifically for therapy again? And what's the magic sauce at services?

[Michael Rice, Chairman & CEO]

Yes, sure. Well, with Sexton, a few minutes ago, I said that we would anticipate that the expected annual revenue range for Sexton for an improved customer therapy is just like it is for biopreservation media. It's $0.5 million to $2 million each annually, and we're in about 140 customer clinical applications with Sexton and in the 3 approved therapies already. So that just fits perfectly. It really does -- and I just got a text from Sean Werner, Dr. Werner, who was running Sexton, who now works for [indiscernible], and he's the CTO of that platform. We've just got a great piece of good news from a large current customer about how they're going to greatly exceed their forecast for this year. So it just could not have come at a better time. And again, Sexton is going to have a banner year if all things hold really, really strong.

As far as the secret sauce, well, the CellSeal vial is proprietary design and has its own unique benefits of ease of use in filling and the proprietary event, and it just really lends itself for small volume doses where you have a great alternative versus putting a little bit of fluid in a big bag and everything that goes wrong with that or could go wrong with that.

On the HPL media side at Sexton, there are some quality and scientific differentiation relative to the other HPL products that are out there, specific to the way that we make the HPL media in [indiscernible], and then the filling machines are just really cool. And the current next-gen filling machine is agnostic. You can bring your own bags and vials and other final containers to the party and it's really lending itself to ushering that degree of automation. And I think just to put the bar on the whole Sexton thing, you've heard us talk about tooling up or starting up a media manufacturing line in [indiscernible] at Sexton for our non-core current [indiscernible] media products, and that's going really well. And all in all, just the whole team at Sexton is a perfect fit, and I can't say enough good about how that one's really worked out.

[Paul Knight, KeyBanc Capital Markets]

Okay. And will a sterile bio be part of Freeze and Thaw?

[Michael Rice, Chairman & CEO]

Yes, but not to divest potentially divest. No, Thaw stays with us regardless, yes, Thaw stays with us.

[Operator]

Your next question comes from Yuan Zhi with B. Riley.

[Yuan Zhi, B. Riley Securities]

So can you guys clarify what was the internal guidance on Media, Freezer and other business segments? And can you elaborate on what are the factors causing the difference between the reported number and the prior guidance or internal guidance in terms of both revenue and gross margin?

[Michael Rice, Chairman & CEO]

Sorry, just to clarify, are you asking me to tell you what our internal plan was for that platform?

[Yuan Zhi, B. Riley Securities]

Internal guidance for Media, Freezer and other business segments. What was the reason to cause the difference between these two?

[Michael Rice, Chairman & CEO]

Well, okay. So all we speak to is the external revenue guidance by platform, which you've seen, which Troy reiterated on the call just a few minutes ago, and as it relates to the shortfall in Freezer revenue, that's all the factors we've been talking about. There is this macro, very well understood now, well-appreciated slowdown in biotech funding, hitting capital equipment much harder than disposable or recurring revenue streams. And that in concert with just the general global economic uncertainty is causing these large global pharma companies to really take a look at and in many cases, pause their purchases for large CapEx pieces of year. Those two things alone is clearly how we speak to that miss there on Freezers in Q1. But I have to say, as I did a few minutes ago, on balance, the opportunity pipeline that we have for Freezers for the rest of the year, the high confidence deals, it's a big number. And if that materializes and then we sort of kind of replicate that for the last 6 months of the year, then we're going to be in good shape.

[Yuan Zhi, B. Riley Securities]

Got it. Thanks for the clarification. And assuming you guys continue to keep Freezer business at the moment, are you still on track to reach 50% adjusted gross margin? And can you clarify which factor had an effect in the last quarter? And what is the gross margin in 1Q without Freezer business?

[Michael Rice, Chairman & CEO]

Yes. We don't do that kind of modeling externally, and clearly, we know that. But we speak to revenue on a platform basis and then we speak to the midterm aspirational goals. So I think I would just -- I would constrain my remarks to what I just said about the downturn in cap equipment funding, coupled with the economic uncertainty that's causing some orders to get delayed.

Now with respect to our confidence to hit our midterm aspirational goals, well, so far, as we sit here with just one quarter in the books, yes. But as I mentioned earlier, if we do go down the path and actually consummate the divestiture of one or both of these businesses, then obviously, we're going to remodel internally and remodel guidance externally and reshape whatever midterm financial aspirational goals we might put out there. Okay?

[Yuan Zhi, B. Riley Securities]

Yes. Got it.

[Operator]

Your next question comes from Carl Byrnes with Northland Capital Markets.

[Carl Byrnes, Northland Capital Markets]

Assuming that you get the divestiture of Stirling and CBS done, would you expect that you'd be able to reaccelerate your M&A strategy, focusing obviously on the high-growth, high-margin segments as you had done very successfully prior to the Stirling acquisition?

[Michael Rice, Chairman & CEO]

Yes. Thanks, Carl. A really good question, and you're getting to a sort of a key dynamic going on here. First of all, I'd say, again, just to remind everybody, it's not divesting is the only option, it's one of several. But if we were to go down that road and complete those from a management bandwidth freeup perspective, you got it, full stop. We would be -- we would be much less encumbered and we'd be focusing on external acquisition targets, obviously, the internal R&D that's going on and the projects that fit would be preserved, but we would certainly have more bandwidth to go and look for other things that look like the way we are now and what we're traditionally really, really good at and what we really understand. So sure, you bet.

[Operator]

We have no further questions at this time. I would now like to turn the call back over to Mike Rice, Chief Executive Officer, for closing remarks.

[Michael Rice, Chairman & CEO]

Thanks, Mallory. I want to thank everyone for your interest in BioLife and your support, and we do look forward to sharing our Q2 numbers and our results with you. Good evening.

[Operator]

This concludes today's conference call. Thank you for joining. You may now disconnect.